Work

Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

Year: 2020

Type: article

Abstract: Adults with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have a poor prognosis. The median overall survival (OS) is 3–8 months with standard of care chemotherapy (SC) [1–3], with m...

Source: Leukemia & lymphoma/Leukemia and lymphoma

DOI: 10.1080/10428194.2020.1751839

Authors: Elias Jabbour, Matthias Stelljes, Anjali S. Advani, Daniel J. DeAngelo, Nicola Gökbuget, David I. Marks, Wendy Stock, Susan O’Brien, Ryan D. Cassaday, Tao Wang, Alexander Neuhof, Erik Vandendries, Hagop Kantarjian

Institutions: The University of Texas MD Anderson Cancer Center, University Hospital Münster, Cleveland Clinic, Dana-Farber Cancer Institute, Goethe University Frankfurt, University Hospital Frankfurt, University Hospitals Bristol NHS Foundation Trust, University of Chicago, University of California, Irvine, University of Washington, Fred Hutch Cancer Center, Pfizer (United States), Pfizer (Germany)

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W3023621931

FWCI: 1.998

Cites: 15

Cited by: 18

Related to: 10